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Abstract - Introduction and Methods: A man diagnosed with sarcoidosis developed partial retrograde amne-
sia followed by three months of depressive symptoms with panic attacks, which remitted with an antidepres-
sant and a benzodiazepine. However, three months later hallucinations and overvalued persecutory ideations 
subsequently emerged, only to show partial response to antipsychotic treatment. Results: Sarcoidosis was 
treated with corticosteroids but serial thorax imaging shows minimal response. Corticosteroid was onboard 
throughout treatment, corresponding with non-remission of psychotic symptoms. There are persistent sub-
jective cognitive difficulties but Mini Mental State Exam score is full. He is currently being treated with es-
citalopram, alprazolam and quetiapine. Conclusion: This case illustrated the dilemma between prolonging 
the corticosteroid therapy for sarcoidosis treatment and the psychiatric sequalae. While symptomatic anti-
psychotic treatment is effective, multi-disciplinary approach is imperative in determining the duration of the 
corticosteroid therapy.  
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Introduction
A 37-year-old risk management executive 
first presented to a private hospital in Septem-
ber 2016 with a three-month history of  chest 
pain and axillary lymph node swelling. There 
was no mood, psychotic, neurotic or cogni-
tive symptoms during those three months. 
There were multiple small palpable axillary 
lymph nodes roughly 1x1 cm in size over the 
right axilla. Physical examination, including a 
full neurological examination, was otherwise 
unremarkable. The initial CT thorax in Sep-
tember 2016 was suggestive of  sarcoidosis, 
with no lung involvement. An urgent histo-
pathological examination in the same month 
showed non caseating granuloma. The pa-
tient was pulsed with IV methylprednisolone 
for 3 days and then started on oral predniso-
lone 60 mg per day and maintained with same 
dose during the whole treatment course up to 
the time of  current presentation.
On his second day of  admission, corre-
sponding to Day 2 of  methylprednisolone, 
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he abruptly developed retrograde amnesia 
to autobiographical memories and a large 
part of  complex procedural skills. There 
was no anterograde amnesia.  For the next 
three months, he also developed low mood 
with loss of  interest, prominent hopeless-
ness and worthlessness, disturbed sleep and 
appetite, with occasional suicidal thoughts. 
However, both brain MRI’s carried out in 
September and October 2016 were normal, 
with no suggestion of  neurosarcoidosis. He 
was started on oral escitalopram 15 mg ON 
and depressive symptoms gradually remit-
ted. He also developed intermittent panic 
attacks beginning in November 2016, peak-
ing at 3-4 times per week. Oral alprazolam 
0.5 mg BD was started and the panic attacks 
reduced to once to twice monthly on treat-
ment.
Two months after his initial presentation, 
in December 2016, he started experiencing 
a mix of  second and third-person auditory 
hallucinations and pseudo-hallucinations 
which were not mood-congruent. Depres-
sive symptoms were in partial remission at 
that time. He also started developing mis-
trust towards others and fears of  others 
harming him, which were not held to delu-
sional intensity. There was no thought alien-
ation, disorganised speech or behaviour, 
or any other delusions or hallucinations. 
Therefore, oral quetiapine was added sub-
sequently for the hallucinations and titrated 
accordingly.
There is no previous medical or surgical 
history. There is no family history of  mental 
illness, no new psychosocial stressors other 
than the illness itself, and no substance or al-
cohol use. He has been highly educated and 
was able to perform complex fiscal calcula-
tions and operate intricate computer soft-
ware.
Mental state examination suggested a 
young-looking man with fair hygiene and 
good rapport. Speech was relevant and co-
herent. He was euthymic with appropriate af-
fect, and there were no perceptual or thought 
disturbances. There were no objective cogni-
tive abnormalities demonstrable. 
A follow-up Mini Mental State Exami-
nation was performed in May 2018 and he 
scored perfectly. No other neurological in-
vestigations were performed in view of  nor-
mal examination and radiology.
Steroid-induced mood, psychotic and 
neurocognitive disorders would be the pro-
visional diagnosis. He fulfils full DSM-5 cri-
teria for major depressive disorder, which 
included low mood, anhedonia, negative 
cognitions, sleep and appetite disturbances, 
as well as suicidal ideations. Panic attacks 
were also temporally associated with depres-
sive symptoms and appear to have also re-
sponded to antidepressant treatment. How-
ever, his depressive disorder has a clear-cut 
temporal relationship to steroid initiation. 
As the patient was medically treated for sar-
coidosis, he was subject to prolonged corti-
costeroid therapy, which may last up to 24 
months. As the patient has consistently been 
on Prednisolone 60 mg OD for prolonged 
duration, he was also at higher risk to de-
velop psychosis, as evidenced by the audito-
ry hallucinations. Apart from that, memory 
impairment has been associated with corti-
costeroid therapy, but the onset of  the am-
nesia has been a peculiar one; he developed 
retrograde amnesia just after 1 day of  cor-
ticosteroid pulse therapy, which is uncom-
mon, as the usual onset would be after 4-5 
days of  therapy.
Differential diagnosis would include neu-
rosarcoidosis with major depressive disorder. 
Albeit rare, it remains a possibility as the psy-
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chotic features and the subjective cognitive 
impairment appeared following the onset of  
symptoms of  sarcoidosis. In addition, the two 
features were not associated with the onset 
and resolution of  the depressive symptoms 
and were still present in conjunction with the 
current non-resolution of  the organic cause. 
However, the points against neurosarcoidosis 
would be that there was no evidence on ex-
amination, imaging, and psychological testing 
to substantiate it.
Oral Escitalopram was titrated up to 15 
mg daily, with oral quetiapine and alprazol-
am added subsequently for hallucinations 
and for panic attacks, respectively. The pa-
tient is currently being treated with oral es-
citalopram 15 mg ON, quetiapine 100 mg 
ON, alprazolam 0.5 mg PRN and Predniso-
lone 60 mg OD. So far there have been no 
focal neurological signs or symptoms. Af-
ter treatment was commenced, there were 
no depressive symptoms. However, there 
are residual auditory hallucinations and the 
persecutory ideations still remain, but of  a 
lesser intensity. In July 2017, six months af-
ter starting oral prednisolone, a thoracic CT 
showed minimal reduction in lymph node 
size. Hence, a video-assisted thoracoscopic 
surgery biopsy of  the lymph nodes was per-
formed in September 2017 with predniso-
lone continued alongside the antidepressant 
and anti-psychotic treatment (last known 
until September 2018). Subsequently the 
patient’s psychotic symptoms significantly 
reduced. As a consequence, he has had to 
relearn many skills and subjectively feels 
slower at his work. He has had to re-learn 
driving, English and Malay language gram-
mar, and how to operate computer software 
at work. However there has been no retro-
grade or anterograde amnesia following that 
date.
Discussion
Sarcoidosis is a systematic disease char-
acterised histopathologically by non-case-
ating granulomas [1]. Its aetiology is as yet 
unknown; infectious, environmental, genetic, 
and immunologic postulations have all been 
considered [2]. At present there is no curative 
treatment for sarcoidosis. However, immu-
nosuppressive and/or immunomodulatory 
drugs can be used to control the disease; with 
systemic corticosteroids remaining the first-
choice therapy in organ- and/or life-threat-
ening sarcoidosis [3]. In a Cochrane review 
of  corticosteroids for pulmonary sarcoid-
osis, treatment with oral steroids for 6 to 24 
months improved thoracic radiograph find-
ings, compared with placebo [4].
However, the prolonged duration of  the 
corticosteroid therapy, although important, 
comes with multiple adverse effects. Cogni-
tive deficits, particularly declarative memory 
deficits, have been well documented during 
both long- and short-term corticosteroid 
therapy. Deficits during short-term therapy 
are consistent with hippocampal dysfunction 
and occur with reversible atrophy of  hip-
pocampal neurons [5]. It is noted that new 
declarative memory deficiencies may emerge 
after just 4 to 5 days of  dexamethasone or 
prednisone therapy, although in this case, ret-
rograde amnesia became prominent after just 
one day of  treatment [6]. 
At the same time, corticosteroids are 
known to cause mood disorders, as well as 
psychosis [7,8]. Although patients in early 
stage of  treatment commonly present with 
mania, prevalence of  depression is higher 
with long-term therapy, which is the case 
with the presented patient, even on low to 
moderate doses [7]. Psychosis, on the other 
hand, is known to occur in 1.3 % of  individu-
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als receiving prednisolone 40 mg per day or 
less; 4 % to 6 % of  patients receiving 41 mg 
to 80 mg per day; and 18.4 % of  patients re-
ceiving more than 80 mg per day [8].
Despite that, the prognosis is excellent, 
with complete recovery in almost 90 % of  
cases [9]. It is widely accepted that in the 
case of  acute corticosteroid-induced psychi-
atric disturbances, atypical antipsychotics ap-
pear to yield the greatest benefit, with fewest 
adverse effects. While antidepressants have 
been found to help in some situations, they 
may exacerbate agitation and psychosis in 
others [10].
Conclusion
Corticosteroids are the mainstay of  treat-
ment for sarcoidosis and in certain cases, they 
can be protracted up to 24 months, based on 
disease progression. Despite its effectiveness, 
clinicians need to consider the risks, especial-
ly psychiatric, of  prolonging the duration of  
the corticosteroid therapy. Although neuro-
leptics and mood stabilisers can be useful in 
managing psychiatric adverse effects, defini-
tive treatment of  this psychiatric issue is still 
the cessation of  the triggering factor. A col-
lective decision should be made between all 
stakeholders in order to determine a suitable 
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Sarkoidoza i terapija kortikosteroidima:  
dilema iz psihijatrijske perspektive
Sažetak - Uvod i metode: Pacijent kojemu je postavljena dijagnoza sarkoidoze razvio je djelomičnu retrograd-
nu amneziju, praćenu tromjesečnim simptomima depresije s napadima panike, koji su se povukli na liječenje 
antidepresivom i benzodiazepinom. Međutim, tri mjeseca kasnije pojavile su se halucinacije te persekutorne 
ideje koje su pokazale svega parcijalni odgovor na liječenje antipsihoticima. Rezultati: Unatoč liječenju sar-
koidoze kortikosteroidima, serijsko snimanje toraksa pokazalo je minimalan odgovor. Tijekom cijelog liječenja 
korišteni su kortikosteroidi, što korelira sa psihotičnim simptoma koji se povlačili. Perzistiraju trajne subjek-
tivne kognitivne poteškoće, ali rezultat Mini Mental State Exam je pun. Trenutno se liječi escitalopramom, 
alprazolamom i kvetiapinom. Zaključak: Ovaj slučaj ilustrira dilemu između produljenog liječenja sarkoidoze 
kortikosteroidima te psihijatrijskih sekvela. Iako je simptomatsko liječenje antipsihoticima učinkovito, multi-
disciplinarni pristup je nužan u određivanju trajanja terapije kortikosteroidima.
Ključne riječi: kortikosteroid, sarkoidoza, psihoza, amnezija

